Get the Stockscreener App
80.82
2.12%
1.68
After Hours:
80.99
0.17
+0.21%
Ionis Pharmaceuticals Inc stock is traded at $80.82, with a volume of 1.47M.
It is up +2.12% in the last 24 hours and up +11.22% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$79.14
Open:
$79.19
24h Volume:
1.47M
Relative Volume:
0.62
Market Cap:
$13.09B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-26.59
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
-1.05%
1M Performance:
+11.22%
6M Performance:
+126.90%
1Y Performance:
+118.37%
1-Day Range:
$78.50
$80.92
1-Week Range:
$77.79
$82.86
52-Week Range:
$23.95
$83.61
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
80.82 | 12.82B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors - Sahm
Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $2,262,960.00 in Stock - MarketBeat
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Is Ionis Pharmaceuticals Inc. (ISI) stock suitable for passive index fundsEarnings Growth Summary & Accurate Entry/Exit Alerts - Newser
What Does the Market Think About Ionis Pharmaceuticals Inc? - Benzinga
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionFed Meeting & Weekly High Return Stock Forecasts - Newser
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leadersMarket Activity Summary & Community Consensus Stock Picks - Newser
Ionis Pharmaceuticals Earnings Notes - Trefis
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD - Investing.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on growth outlook - Investing.com Canada
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug By Investing.com - Investing.com Canada
Granite Investment Partners LLC Trims Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Why Ionis Pharmaceuticals Inc. (ISI) stock could break out in 2025July 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
American Century Companies Inc. Raises Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
How robust is Ionis Pharmaceuticals Inc. (ISI) stock financial position - Newser
What hedge fund activity signals for Ionis Pharmaceuticals Inc. stock2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 52-Week HighStill a Buy? - MarketBeat
Ionis Pharmaceuticals (IONS) Gains FDA Breakthrough Therapy Desi - GuruFocus
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' Zilganersen (IONS) - GuruFocus
Ionis Pharmaceuticals' Investigational Alexander Disease Treatment Granted Breakthrough Therapy Designation - marketscreener.com
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug - Investing.com
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire
How Ionis Pharmaceuticals Inc. (ISI) stock performs during market turbulenceEntry Point & Low Risk Entry Point Tips - Newser
FDA grants breakthrough therapy status to Ionis’ olezarsen for severe HTG - Investing.com Australia
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen - Sahm
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen - Yahoo Finance
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? - Yahoo Finance
Ionis receives U.S. FDA breakthrough therapy designation for olezarsen for severe hypertriglyceridemia - marketscreener.com
Ionis Says Olezarsen Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia - marketscreener.com
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuti - GuruFocus
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - The Manila Times
Ionis Pharmaceuticals shares up 3.5% premarket after co receives FDA breakthrough therapy designation for olezarsen for SHTG - marketscreener.com
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) - Business Wire
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):